Oncology Today with Dr Neil Love

47:06

Diffuse Large B-Cell Lymphoma — An Interview with Dr...

Oncology Today with Dr Neil Love ·

2026/10/05

Featuring an interview with Dr L Elizabeth Budde, including the following topics:Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and

en

50:33

Lung Cancer — Proceedings from a Symposium Held in...

Oncology Today with Dr Neil Love ·

2026/10/04

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)EGFR Mutations (2:23)HER2 Alterations (22:40)Available and Investigational Immunotherapies (32:14)Small Cell Lung Cancer (40:48)CME information and select publications

en

52:24

Prostate Cancer with PTEN Deficiency — An Interview...

Oncology Today with Dr Neil Love ·

2026/10/02

Featuring an interview with Dr Neeraj Agarwal, including the following topics:Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)Managing treatment-related adverse events from

en

23:25

HER2-Positive Gynecologic Cancers — Microlearning...

Oncology Today with Dr Neil Love ·

2026/10/01

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A

en

50:22

Diffuse Large B-Cell Lymphoma — Proceedings from a...

Oncology Today with Dr Neil Love ·

2026/10/01

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications

en

51:21

Ovarian and Endometrial Cancer — Proceedings from a...

Oncology Today with Dr Neil Love ·

2026/09/30

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)Ovarian Cancer (2:22)Endometrial Cancer (37:48)CME information and select publications

en

58:01

For Oncology Nurses: Non-Small Cell Lung Cancer with...

Oncology Today with Dr Neil Love ·

2026/09/30

Featuring an interview with Dr Alexander E Drilon, including the following topics:Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion

en

48:25

Glucocorticoid Receptor Antagonists for Ovarian...

Oncology Today with Dr Neil Love ·

2026/09/29

Featuring an interview with Professor Nicoletta Colombo, including the following topics:Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study

en

50:22

Gastroesophageal Cancers — Proceedings from a...

Oncology Today with Dr Neil Love ·

2026/09/28

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)Management of HER2-Positive Gastroesophageal Cancer (25:11)Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for

en

54:25

Chronic Lymphocytic Leukemia — Proceedings from a...

Oncology Today with Dr Neil Love ·

2026/09/28

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications

en

01:28:21

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia...

Oncology Today with Dr Neil Love ·

2026/09/25

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications

en

09:31

HER2-Positive Gynecologic Cancers — Microlearning...

Oncology Today with Dr Neil Love ·

2026/09/24

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A LedermannCME information and select publications

en

49:41

Antibody-Drug Conjugates for Multiple Myeloma — An...

Oncology Today with Dr Neil Love ·

2026/09/23

Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)Progression-free survival estimates with current quadruplet induction and

en

23:55

Metastatic Triple-Negative Breast Cancer — 5-Minute...

Oncology Today with Dr Neil Love ·

2026/09/22

Featuring perspectives from Dr David W Cescon, including the following topics:Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)CNS activity of TROP2-directed antibody-drug conjugates (5:36)Autoimmune considerations with immunotherapy (10:09)Treatment of oligoprogressive advanced breast cancer (17:31)CME information and select publications

en

29:44

Metastatic Triple-Negative Breast Cancer — 5-Minute...

Oncology Today with Dr Neil Love ·

2026/09/21

Featuring perspectives from Dr David W Cescon, including the following topics:First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)Adverse events (19:39)CME information and select publications

en

58:14

Gynecologic Cancers — Reviewing Key Presentations...

Oncology Today with Dr Neil Love ·

2026/09/17

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:Introduction (0:00)Preventing Ovarian Cancer (1:04)Endometrial Cancer (5:27)Ovarian Cancer (25:36)Cervical Cancer (54:04)CME information and select publications

en

25:57

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Oncology Today with Dr Neil Love ·

2026/09/16

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)Case: A woman in her early 70s with Lynch syndrome and

en

36:28

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Oncology Today with Dr Neil Love ·

2026/09/16

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)Case: A man in his early 50s with metastatic bladder cancer receives

en

01:29:36

Breast Cancer — Reviewing Key Presentations from the...

Oncology Today with Dr Neil Love ·

2026/09/15

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)CME information and select publications

en

26:21

Low-Grade Serous Ovarian Cancer — Rapid Case Review:...

Oncology Today with Dr Neil Love ·

2026/09/14

Featuring perspectives from Dr Rachel N Grisham, including the following topics:Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on

en

All Episodes

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media